The Mechanism of monitoring of adverse drug reaction cluster signals and disposal at the provincial level

doi:10.19803/j.1672-8629.2022.02.14

Abstract

Abstract: Objective To explore the working mechanism of monitoring of adverse drug reaction cluster signals and disposal at the provincial level. Methods Based on ways of monitoring in Shandong Province, the patterns and characteristics of adverse drug reaction cluster signals were summarized, specific requirements were clarified and advice on improving the monitoring of ADR cluster signals was given. Results and Conclusion The monitoring and disposal of adverse drug reaction cluster signals requires that the main responsibilities of drug marketing authorization holders are fulfilled, risk control be given the top priority, multi-sided collaboration and closed-loop disposal be ensured.

Key words: adverse drug reaction, drug marketing authorization holder, cluster, signal, disposal

CLC Number:

R95R994.11

LU Changfei, CUI Xiaokang, LIU Wenwen, ZHANG Huaqi, GAO Wenzheng, WU Shifu. The Mechanism of monitoring of adverse drug reaction cluster signals and disposal at the provincial level[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 180-184.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2022.02.14

https://zgywjj.magtechjournal.com/EN/Y2022/V19/I2/180

References

[1] CFDA. CFDA has ordered the immediate stop of the sale and use of six batches of riboflavin sodium phosphate injection from Hubei Tongji Banda Ebei Pharmaceutical Co., Ltd.[EB/OL].(2014-08-12)[2020-11-13].https://www.nmpa.gov.cn/yaopin/ypjgdt/20140812202901646.html.
[2] CFDA. CFDA has ordered a full recall of the products and investigated Anhui Lianyi Pharmaceutical Co., Ltd.[EB/OL].(2015-02-17)[2020-11-13].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20150217141701737.html.
[3] CFDA. Notice concerning quality issues of Honghua injection and Xiyanping injection from Shanxi Zhendong Ante Biopharmaceutical Co., Ltd. and Jiangxi Qingfeng Pharmaceutical Co., Ltd. (No. 153 of2017).[EB/OL].(2017-09-23)[2020-11-13].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20170923225201502.html.
[4] CDR. CDR issued the announcement on the annual report for national ADR monitoring (2019)[EB/OL].(2020-04-10)[2020-11-13].http://www.cdr-adr.org.cn/tzgg_home/202004/t20200410_47300.html.
[5] FENG HY, HOU YF, WU GZ, et al.The establishing and running of pre-warning system on adverse event cluster signal[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2012, 9(12): 745-748.
[6] FENG HY, YANG L, SONG QJ, et al.Proposal and practice of building the early warning system on cluster adverse drug events based on the adverse drug reaction monitoring[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015,12(11): 665-668.
[7] FENG HY, GE WC, XIA XD, et al.Construction and practice of early warning system sharing platform on cluster adverse drug events[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(12): 727-730.
[8] FENG HY, LIU J, DONG D, et al.Analysis of the risk factors influencing the adverse drug cluster events early warning system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(4): 219-222.
[9] HUANG QQ, SUN J.Analysis of adverse events aggregation signals in Jiangsu province from 2021 to the First Half of 2017[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2018, 27(1): 42-44.
[10] SUN J, HUANG QQ, GAN G, et al.Discussion on the strategy of drug manufactures to deal with the adverse drug event clustering signal[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(11): 671-673.
[11] NMPA. Notice of direct reporting of adverse drug reactions by MAH (No. 66 of2018)[EB/OL].(2018-09-30)[2020-11-13].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180930174301286.html.
[12] GE WC.Analysis of cluster signals of adverse drug events in Anhui province[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 123-125, 128.

[1]	LI Mingying, ZHANG Xiaoxia, SUN Xiaoli, ZHAO Yan, HE Miao, LI Yanling, DUAN Wei, YANG Ou. Effect of Sugammadex on Recovery of Patients after Laparoscopic Total Pelvic Floor Reconstruction [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 896-901.
[2]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[3]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[4]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[5]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[6]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[7]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.
[8]	YANG Xin, YANG Baochun, YANG Yang, SHAO Huan. One Case of Multiple Endocrine Adverse Effect Caused by Sintilimab [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 947-949.
[9]	REN Yuke, JIANG Hua, LI Lulu, LI Shuangxing, HUO Guitao, YANG Yanwei, ZHANG Di, HUANG Ying, GENG Xingchao, LIN Zhi, QU Zhe. Research Advances in the Pathogenesis of Cytokine Release Syndrome Induced by CAR-T Cell Therapy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 735-741.
[10]	WANG Chunting, CHEN Yafei. Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779.
[11]	ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
[12]	LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793.
[13]	CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun. 48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
[14]	CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun. Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
[15]	LIN Lu, ZHAO Anzhi, CHEN Jinhui, LI Zhongwen, HUANG Guohua, ZHONG Shilong. One Case of Delayed Hypersensitivity Reactions Caused by Cefotaxime Sodium and Sulbactam Sodium for Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 809-811.